Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010666299> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W2010666299 endingPage "P04.153" @default.
- W2010666299 startingPage "P04.153" @default.
- W2010666299 abstract "Objective: To determine the safety and tolerability of zinc methionine (Optizinc) at high doses in patients with ALS and to measure levels of BMAA in blood and urine. Background Previous studies have identified β-methylamino-L-alanine (BMAA), as the potential neurotoxin responsible for the Guamanian ALS complex. BMAA has been shown to be an avid binder of zinc. Interestingly, glutamate also requires zinc as a potential modulator at the synapse. This competitive binding to Zinc could lead to a state where glutamate and BMAA could be left unbound to zinc increasing their neurotoxicity. We hypothesize that by exposing patients to high levels of zinc, BMAA and glutamate would be kept in a bound complex with zinc, thereby decreasing the potential neurotoxicity and slowing down the disease course. Design/Methods: 10 patients diagnosed with sporadic ALS on stable doses of riluzole were enrolled. Patients received Optizinc at 30 mg TID and copper 2 mg QD for three months. Blood and urine were collected for BMAA analysis at baseline and at month 3. ALSFRSR, safety labs, zinc and copper plasma levels were measured monthly. FVC was measured at baseline and at month 3. Results: Eight patients completed the study. All patients tolerated Optizinc at 90 mg/d. Zinc levels were maintained between 80% and 125% of the ULN.Copper levels were maintained within the normal range in all patients. The rate of ALS progression, as measured by monthly change in ALS-FRS-R scores, seemed to improve over the course of treatment. All patients who completed the study opted to stay on treatment. Levels of BMAA from the blood and urine are being analyzed. Conclusions: Optizinc at 90mg/d was well tolerated in patients with ALS. This safety study suggests that larger and longer placebo conrolled study of zinc in patient with ALS should be performed. Disclosure: Dr. Levine has received personal compensation for activities with Lilly, Pfizer, and Talecris. Dr. Hank has nothing to disclose. Dr. Saperstein has received personal compensation for activities with Talecris, CSL Behring, Eli Lilly, and Corinthian Reference Lab. Dr. Bradley has nothing to disclose. Dr. Cox has nothing to disclose." @default.
- W2010666299 created "2016-06-24" @default.
- W2010666299 creator A5001954609 @default.
- W2010666299 creator A5018425320 @default.
- W2010666299 creator A5025085620 @default.
- W2010666299 creator A5065806824 @default.
- W2010666299 creator A5070845239 @default.
- W2010666299 date "2012-04-22" @default.
- W2010666299 modified "2023-09-27" @default.
- W2010666299 title "A Pilot Trial of Zinc in Patients with ALS (P04.153)" @default.
- W2010666299 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.153" @default.
- W2010666299 hasPublicationYear "2012" @default.
- W2010666299 type Work @default.
- W2010666299 sameAs 2010666299 @default.
- W2010666299 citedByCount "0" @default.
- W2010666299 crossrefType "journal-article" @default.
- W2010666299 hasAuthorship W2010666299A5001954609 @default.
- W2010666299 hasAuthorship W2010666299A5018425320 @default.
- W2010666299 hasAuthorship W2010666299A5025085620 @default.
- W2010666299 hasAuthorship W2010666299A5065806824 @default.
- W2010666299 hasAuthorship W2010666299A5070845239 @default.
- W2010666299 hasConcept C126322002 @default.
- W2010666299 hasConcept C168563851 @default.
- W2010666299 hasConcept C1862650 @default.
- W2010666299 hasConcept C191897082 @default.
- W2010666299 hasConcept C192562407 @default.
- W2010666299 hasConcept C2994577977 @default.
- W2010666299 hasConcept C535196362 @default.
- W2010666299 hasConcept C71924100 @default.
- W2010666299 hasConceptScore W2010666299C126322002 @default.
- W2010666299 hasConceptScore W2010666299C168563851 @default.
- W2010666299 hasConceptScore W2010666299C1862650 @default.
- W2010666299 hasConceptScore W2010666299C191897082 @default.
- W2010666299 hasConceptScore W2010666299C192562407 @default.
- W2010666299 hasConceptScore W2010666299C2994577977 @default.
- W2010666299 hasConceptScore W2010666299C535196362 @default.
- W2010666299 hasConceptScore W2010666299C71924100 @default.
- W2010666299 hasIssue "Meeting Abstracts 1" @default.
- W2010666299 hasLocation W20106662991 @default.
- W2010666299 hasOpenAccess W2010666299 @default.
- W2010666299 hasPrimaryLocation W20106662991 @default.
- W2010666299 hasRelatedWork W2050903545 @default.
- W2010666299 hasRelatedWork W2218480077 @default.
- W2010666299 hasRelatedWork W2342864667 @default.
- W2010666299 hasRelatedWork W2518044622 @default.
- W2010666299 hasRelatedWork W2595222983 @default.
- W2010666299 hasRelatedWork W2752610348 @default.
- W2010666299 hasRelatedWork W2773362255 @default.
- W2010666299 hasRelatedWork W3038282643 @default.
- W2010666299 hasRelatedWork W4214947900 @default.
- W2010666299 hasRelatedWork W2762959529 @default.
- W2010666299 hasVolume "78" @default.
- W2010666299 isParatext "false" @default.
- W2010666299 isRetracted "false" @default.
- W2010666299 magId "2010666299" @default.
- W2010666299 workType "article" @default.